Medical News

---

• Mood episodes impair QoL in young adults
• Mood episodes impair QoL in young adults
• Default mode network impaired in young adults at risk for psychosis
• Default mode network impaired in young adults at risk for psychosis
• Lapatinib benefits found for HER2-positive early-stage patients
• ¹⁸FDG–PET–CT improves breast cancer staging
• Sit–rise test may guide mortality risk stratification
• Surgery poses cardiac risk to lupus women
• Long-term antiviral HBV treatment advocated
• Lapatinib benefits found for HER2-positive early-stage patients
• ¹⁸FDG–PET–CT improves breast cancer staging
• Abiraterone improves outcomes for prostate cancer prior to chemo
• Partial nephrectomy maintains renal function in cT1a RCC
• Preop features predict pathology of small renal masses
• Nephron-sparing surgery beats ablation for small renal masses
• Cytokine rise signals RCC progression
• ‘Ambu-lysis’ edges closer for stroke patients
• Abiraterone improves outcomes for prostate cancer prior to chemo

Mood episodes impair QoL in young adults Posted: 17 Dec 2012 04:00 PM PST Mood episodes have a significant negative effect on quality of life in young adults, even among those without diagnosed bipolar disorder, Brazilian researchers report.

Mood episodes impair QoL in young adults Posted: 17 Dec 2012 04:00 PM PST Mood episodes have a significant negative effect on quality of life in young adults, even among those without diagnosed bipolar disorder, Brazilian researchers report.

Default mode network impaired in young adults at risk for psychosis Posted: 17 Dec 2012 04:00 PM PST Young adults at genetic risk for psychosis show reduced activity in the default mode network area of the brain compared with those without such a family history, researchers report.

Default mode network impaired in young adults at risk for psychosis Posted: 17 Dec 2012 04:00 PM PST Young adults at genetic risk for psychosis show reduced activity in the default mode network area of the brain compared with those without such a family history, researchers report.

Lapatinib benefits found for HER2-positive early-stage patients Posted: 16 Dec 2012 04:00 PM PST Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology.

<sup>18</sup>FDG–PET–CT improves breast cancer staging Posted: 16 Dec 2012 04:00 PM PST A prospective study has shown fluorodeoxyglucose positron emission tomography/computed tomography to be a powerful tool for the detection of nodal and distant metastatic disease in patients with breast cancer.

Sit–rise test may guide mortality risk stratification Posted: 16 Dec 2012 04:00 PM PST Assessing how much support a middle-aged or elderly person requires to sit and rise from the floor could be an indicator of all-cause mortality risk, researchers say.

Surgery poses cardiac risk to lupus women Posted: 16 Dec 2012 04:00 PM PST Women with systemic lupus erythematosus are at significantly increased risk for short-term perioperative adverse cardiovascular events, find researchers.

Long-term antiviral HBV treatment advocated Posted: 16 Dec 2012 04:00 PM PST Study results support the long-term use of tenofovir disoproxil fumarate for chronic hepatitis B virus, showing that it can suppress the virus and lead to regression of fibrosis and cirrhosis in patients after 5 years' treatment.

Lapatinib benefits found for HER2-positive early-stage patients Posted: 16 Dec 2012 04:00 PM PST Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology.

<sup>18</sup>FDG–PET–CT improves breast cancer staging Posted: 16 Dec 2012 04:00 PM PST A prospective study has shown fluorodeoxyglucose positron emission tomography/computed tomography to be a powerful tool for the detection of nodal and distant metastatic disease in patients with breast cancer.

Abiraterone improves outcomes for prostate cancer prior to chemo Posted: 16 Dec 2012 04:00 PM PST Treatment with abiraterone acetate, an androgen biosynthesis inhibitor, may benefit patients with progressive metastatic castration-resistant prostate cancer who have not yet undergone chemotherapy, report researchers.

Partial nephrectomy maintains renal function in cT1a RCC Posted: 16 Dec 2012 04:00 PM PST Partial nephrectomy offers a similar magnitude of benefit in patients with clinical T1b versus cT1a renal cell carcinoma, Japanese researchers have shown.

Preop features predict pathology of small renal masses Posted: 16 Dec 2012 04:00 PM PST Researchers have identified preoperative clinical and tumor characteristics that predict the risk for malignancy in patients undergoing partial nephrectomy for small renal masses.

Nephron-sparing surgery beats ablation for small renal masses Posted: 16 Dec 2012 04:00 PM PST Nephron-sparing surgery is more effective than ablation for the treatment of clinical stage T1a renal masses, research findings show.

Cytokine rise signals RCC progression Posted: 16 Dec 2012 04:00 PM PST Progression of renal cell carcinoma is frequently preceded by a rise in levels of proangiogenic cytokines, Italian researchers have found.

‘Ambu-lysis’ edges closer for stroke patients Posted: 16 Dec 2012 04:00 PM PST A pilot trial of giving suitable stroke patients intravenous thrombolysis before their arrival in hospital has produced promising results.

Abiraterone improves outcomes for prostate cancer prior to chemo Posted: 16 Dec 2012 04:00 PM PST Treatment with abiraterone acetate, an androgen biosynthesis inhibitor, may benefit patients with progressive metastatic castration-resistant prostate cancer who have not yet undergone chemotherapy, report researchers.

You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610